Community prevalence and distribution of dengue virus serotype based on antibody neutralization assay in Jakarta, Indonesia
Abstract
Background Dengue infection is still rising globally despite the implementation of preventive efforts in many endemic countries. Monitoring the circulation of dengue virus (DENV) serotypes is not performed routinely in the Indonesian national surveillance program, primarily due to high cost and effort.
Objective To evaluate the distribution of DENV serotypes based on serological profile and neutralizing antibody level against all four DENV serotypes in Jakarta, Indonesia.
Methods This cross-sectional study was performed as part of a dengue vaccine effectiveness study, 10 years after a dengue vaccination program was initiated. It was conducted in five community public health centers in Jakarta in subjects aged 12 years and above who had not received the dengue vaccine. We collected serum samples and DENV neutralizing antibody titers were measured using a plaque reduction neutralization test (PRNT).
Results Eighty healthy subjects with a median age of 15 (range 12-27) years were enrolled. The highest median antibody titer was that to DENV-2 [898 (range 29-91558) 1/dil], followed by that to DENV-3 [297.5 (range 10-36091); 1/dil], DENV-1 [288 (range 0-68237) 1/dil], and DENV-4 [164 (range 0-35812) 1/dil]. Neutralizing antibodies against the four DENV serotypes were found in all the 5 districts studied in Jakarta. A multitypic neutralizing antibody profile was observed in the majority (74/80 subjects; 92.5%). Three subjects were naïve.
Conclusion All four dengue serotypes are widely circulating in Jakarta based on neutralizing antibody detection in the community, with the highest neutralizing antibody titer being against DENV-2, followed by DENV-3, DENV-1 and DENV-4.
References
2. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue: a continuing global threat. Nat Rev Microbiol. 2010;8:S7-16. DOI:https://doi.org/10.1038/nrmicro2460
3. Carrington LB, Simmons CP. Human to mosquito transmission of dengue viruses. Front Immunol. 2014;5:290. DOI: https://doi.org/10.3389/fimmu.2014.00290
4. Bhatt S, Gething PQ. Brady OF, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496:504-7. DOI: https://doi.org/10.1038/nature12060
5. World Health Organization. Global strategy for dengue prevention and control 2012-2020. 2nd edition. Geneva: World Health Organization; 2012.
6. Wilder-Smith A, Ooi EE, Vasudevan SG, Gubler DJ. Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr Infect Dis Rep. 2010;12:157-64. DOI: https://doi.org/10.1007/s11908-010-0102-7
7. Sasmono RT, Taurel AF, Prayitno A, Sitompul H, Yohan B, Hayati RF, et al. Dengue virus serotype distribution based on serological evidence in pediatric urban population in Indonesia. PLoS Negl Trop Dis. 2018;12:e0006616-26. DOI: https://doi.org/10.1371/journal.pntd.0006616
8. Prayitno A, Taurel AF, Nealon J, Satari HI, Karyanti MR, Sekartini R, et al. Dengue seroprevalence and force of primary infection in a representative population of urban dwelling Indonesian children. PLoS Negl Trop Dis. 2017;11:e0005621-37. DOI: https://doi.org/10.1371/journal.pntd.0005621
9. Sasmono RT, Santoso MS, Pamai YWB, Yohan B, Afida AM, Denis D, et al. Distinct dengue disease epidemiology, clinical, and diagnosis features in western, central, and eastern regions of Indonesia, 2017-2019. Front Med. 2020;7:582235. DOI: https://doi.org/10.3389/fmed.2020.582235
10. Dewi BE, Nainggolan L, Sudiro TM, Chenderawasi S, Goentoro PL, Sjatha F. Circulation of various dengue serotypes in a community-based study in Jakarta, Indonesia. Jpn J Infect Dis. 2021;74:17-22. DOI: https://doi.org/10.7883/yoken.JJID.2019.431
11. Timiryasova TM, Bonaparte MI, Luo P, Zedar R, Hu BT, Hildreth SW. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg. 2013;88:962-70. DOI: https://doi.org/10.4269/ajtmh.12-0461
12. Lardo S, Utami Y, Yohan B, Tarigan SM, Santoso WD, Nainggolan L, et al. Concurrent infections of dengue viruses serotype 2 and 3 in patient with severe dengue from Jakarta, Indonesia. Asian Pac J Trop Med. 2016;9:134-40. DOI: https://doi.org/10.1016/j.apjtm.2016.01.013
13. Seto D, Budianti A, Dewi BE, Cucunawangsih, Chandra R, Chaidir J, et al. Association between dengue virus serotypes and type of viral infection in Department of Child Health, Cipto Mangunkusumo hospital, Jakarta, Indonesia. Dengue Bulletin. 2011;35:206-14. https://www.researchgate.net/publication/235513485_Association_between_dengue_virus_serotypes_and_type_of_dengue_viral_infection_in_Department_of_Child_Health_Cipto_Mangunkusumo_Hospital_Jakarta_Indonesia#fullTextFileContent
14. Harapan H, Michie A, Yohan B, Shu PY, Mudatsir M, Sasmono RT, et al. Dengue viruses circulating in Indonesia: a systematic review and phylogenetic analysis of data from five decades. Rev Med Virol. 2019;29:e2037. DOI: https://doi.org/10.1002/rmv.2037
15. Coller B, Clements D. Dengue vaccines: progress and challenges. Curr Opin Immunol. 2011;23:391-8. DOI: https://doi.org/10.1016/j.coi.2011.03.005
16. Hou J, Ye W, Chen J. Current development and challenges of tetravalent live-attenuated dengue vaccines. Front Immunol. 2022;13:840104. DOI: https://doi.org/10.3389/fimmu.2022.840104
17. Ramadona AL, Lazuardi L, Hii YL, Holmner Å, Kusnanto H, Rocklöv J. Prediction of dengue outbreaks based on disease surveillance and meteorological data. PLOS ONE. 2016;11: e0152688 DOI: https://doi.org/10.1371/journal.pone.0152688
18. Kusriastuti R, Sutomo S. Evolution of dengue prevention and control programme in Indonesia. Dengue Bull. 2005;29:1-7. https://iris.who.int/bitstream/handle/10665/164013/dbv29p1.pdf
19. World Health Organization. Comprehensive guidelines for prevention and control of dengue and dengue haemorrhagic fever, revised and exopanded. 2nd ed. India: WHO, Regional Office for South-East Asia; 2011. https://iris.who.int/bitstream/handle/10665/204894/B4751.pdf?sequence=1&isAllowed=y
20. Cavallier P, Tarantola A, Leo Y, Lover A, Rachline A, Duch M, et al. Early diagnosis of dengue disease severity in a resource-limited Asian country. BMC Infect Dis. 2016;16:512-9. DOI: https://doi.org/10.1186/s12879-016-1849-8
21. Wilder-Smith A. Dengue vaccine development: status and future. Bundesgesundheitsbl. 2020;63:40-4. DOI: https://doi.org/10.1007/s00103-019-03060-3
22. Plennevaux E, Sabchareon A, Limkittikul K, Chanthavanich P, Sirivichayakul C, Moureau A, et al. Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: utility for efficacy evaluation and impact of future vaccine introduction. Vaccine. 2016;34:2707-12. DOI: https://doi.org/10.1016/j.vaccine.2016.04.028
Copyright (c) 2025 Mulya Rahma Karyanti
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Accepted 2024-10-15
Published 2025-02-18
